Answer
Yes, nonacog beta pegol (Refixia) carries a potential risk of thromboembolic episodes, although high-purity factor IX products like Refixia are rarely associated with these adverse reactions.
Sources for this answer
- Refixia 500 IU powder and solvent for solution for injectionNovo Nordisk Limited · emc · SmPC §4.8 Undesirable effects · Version 4Document updated
Sources checked